Germany Cancer Immunotherapy Market Analysis

Germany Cancer Immunotherapy Market Executive Analysis

Germany's cancer immunotherapy market is expected to witness growth from $4.1 Bn in 2022 to $6.2 Bn in 2030 with a CAGR of 5.3% for the forecasted year 2022-30. To strengthen Germany's position as a leader in global health and one of WHO's most ardent supporters, the Federal Ministry of Health (BMG) today announced a $142 Mn donation to the organization for 2023. The donation helps WHO with important priorities like antibiotic resistance, health emergencies, strengthening health systems, and WHO reforms. The money will go toward the WHO-BMG cooperative initiative, the WHO response to COVID-19, and the WHO Hub for Pandemic and Epidemic Intelligence in Berlin. Germany has been the leading donor to ACT-Accelerator, a global effort to promptly develop, produce, and fairly distribute COVID-19 vaccines, tests, and treatments. In the bienniums 2020–2021 and 2022, Germany was WHO's highest overall contributor and second in those years.

In Germany, there were reportedly 265,000 men and 233,000 women who received a new cancer diagnosis in 2018. As a result, the total annual number of new cases has remained constant for the past ten years at roughly 500,000. This suggests that, despite some uneven tendencies for the many types of cancer, overall cancer incidence rates have decreased modestly as a result of the aging population.

Even at its advanced stages, cancer can be successfully resisted by human immunity. As a result, cancer immunotherapy is becoming a more crucial field of oncology, and researchers are working very hard to create new immunotherapy methods. Immune checkpoint inhibitors, cancer vaccines, and monoclonal antibodies have already been used successfully in German cancer clinics. One of the most important developments in medicine in recent years is CAR T-cell therapy. The treatment of lymphomas, multiple myelomas, and leukaemias has been accomplished with success. The method is refined over time. The indications for its use are growing as more clinical trials are being completed. T-cell immunotherapy will likely soon be employed in Germany for a wide variety of different cancers. Because immune cells' genes are altered in the lab, immunotherapy and gene therapy are both used as treatment options. They are given chimeric antigen receptors (CARs), which aid T-cells in binding to a tumour-specific antigen.

Market Dynamics

Market Growth Drivers

In the treatment of many tumours, immunotherapy has demonstrated encouraging outcomes, and its use is expanding in Germany. New immunotherapy medications are becoming more widely available, and patients and healthcare professionals are becoming more aware of their advantages, which is driving this trend. The German government has put in place a number of programs to encourage the advancement and use of immunotherapy. For instance, the government has built regulatory frameworks to assist the approval and uptake of new immunotherapy medicines and has funded research into these therapies. In Germany, academic research institutions and pharmaceutical businesses work together to advance immunotherapy research and development. Collaborations between pharmaceutical corporations and academic institutions accelerate their development and distribution of novel immunotherapy therapies thus leading to the expansion of Germany's cancer immunotherapy market.

Market Restraints

Immunotherapy medications can be costly, which may limit their accessibility to individuals with limited financial resources. Despite the fact that the German healthcare system pays for cancer therapies, including immunotherapy, some patients can still have financial difficulties in getting these treatments.  Immunotherapy medications could have difficult patient selection standards, which could sometimes prevent their widespread use. Immunotherapy treatment may not be available to patients who don't meet the requirements, which could restrict the treatment's acceptance and commercial expansion. Immunotherapy medications may not be readily available to patients until the regulatory approval procedure is completed, which can be complicated and time-consuming. This can restrict the German cancer immunotherapy market adoption and expansion.

Competitive Landscape

Key Players

• BioNTech (DEU)- CARs, T cell receptors (TCRs), recombinant cytokines, and tailored mRNA are all part of BioNTech's much bigger pipeline. A wide range of immuno-oncology treatments based on mRNA, antibodies, and CAR-T cells are now in their pipeline
• Affimed Therapeutics (DEU)- The innate immune system is the company's primary emphasis. Affimed creates cell engagers, which are multi-specific antibodies, using their ROCK platform
• Heidelberg Pharma (DEU)- The preclinical stage of Heidelberg Pharma's lead product, which targets B cell maturation antigen (BCMA), is currently being advanced
• Immatics (DEU)- The company develops individualized immuno-oncology treatments by genetically modifying patient T cells to express TCRs that target the patient's malignancy
• Medigene (DEU)- This company creates dendritic cell vaccines (DCs), T cell-specific antibodies (TABs), and modified TCRs known as TCR-Ts
• Bayer
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer
• Eli Lily
• Novartis

Notable Deals

January 2023- The same mRNA technology will be used in a cancer treatment being tested in Britain by the German pharmaceutical company BioNTech, which created the ground-breaking COVID-19 vaccination. A new deal between BioNTech and the British government includes the initiative as part of its focus on cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UK.

Healthcare Policies and Regulatory Landscape

The statutory health insurance system in Germany serves as the primary regulatory framework for cancer health coverage and reimbursement practices. Patients with cancer are entitled to comprehensive medical care under this system, including cancer therapies like immunotherapy, at no or very low cost. In Germany, statutory health insurance funds pay the costs of cancer treatments, including immunotherapy. The price is determined by a predetermined rate agreed upon between the healthcare providers and the funds. In Germany, cancer treatment reimbursement rules are based on the DRG (diagnosis-related group) classification system. The DRG system bases its flat-rate payments on the patient's diagnosis and received care. This method bases the cost of cancer therapies, including immunotherapy, on the DRG given to the patient's diagnosis and course of care. Additionally, patients in Germany can be qualified for financial aid schemes or clinical trials that open up access to cancer therapies like immunotherapy. These initiatives and trials might be supported by the public sector, the healthcare industry, or non-profit groups.